{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for angiotensin root_names_stdName in Standardized Name (approximate match)
Status:
Possibly Marketed Outside US
First approved in 1950
Source:
NDA007073
Source URL:
Class:
POLYMER
Cellacefate is a commonly used polymer phthalate in the formulation of pharmaceuticals, such as the enteric coating of tablets or capsules and for controlled release formulations. Cellacefate's use in enteric coatings allows tablets to remain intact in the unfavorable gastric acid secretion of the stomach, but dissolve in the more basic areas of the duodenum, thus protecting the stomach from ulceration or allowing greater absorption form the duodenum. Cellacefate is a reaction product of phthalic anhydride and a partial acetate ester of cellulose.
Status:
Possibly Marketed Outside US
Source:
NDA021612
(1993)
Source URL:
First approved in 1950
Source:
NDA007073
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
ANDA091135
(2012)
Source URL:
First approved in 1948
Source:
NDA018279
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Over-the-CounterOTCDrugs/StatusofOTCRulemakings/ucm072609.htm oral health care:tooth desensitizer poloxamer 407
Source URL:
First approved in 1947
Source:
NDA017116
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
505G(a)(3)
(2014)
Source URL:
First approved in 1938
Source:
Belladonna and Opium by Padagis US LLC
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
21 CFR 333
(1997)
Source URL:
First approved in 1938
Source:
Belladonna and Opium by Padagis US LLC
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
NCT03386240: Phase 4 Interventional Completed Surgical Site Infection
(2018)
Source URL:
Class:
POLYMER
Status:
US Approved Rx
(2016)
Source:
NDA207648
(2016)
Source URL:
First approved in 1975
Source:
INTRALIPID 10% by FRESENIUS
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
US Approved Rx
(2013)
First approved in 1942
Class:
STRUCTURALLY DIVERSE
Status:
US Approved Rx
(2016)
Source:
NDA207648
(2016)
Source URL:
First marketed in 1921
Class:
STRUCTURALLY DIVERSE
